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Abstract
Background Randomised controlled trials (RCTs) in surgery
are complex to design and conduct and face unique challenges
compared to trials in other specialties. The appropriate selec-
tion, measurement and reporting of outcomes are one aspect
that requires attention. Outcomes in surgical RCTs are often
ill-defined, inconsistent and at high risk of bias in their assess-
ment and historically, there has been an undue focus on short-
term outcomes and adverse events meaning the value of trial
results for clinical practice and decision-making is limited.
Purpose This review addresses three key problems with sur-
gical trial outcomes—choosing the right outcomes for the trial
design and purpose, selecting relevant outcomes to measure
from the range of possible outcomes, andmeasuring outcomes
with minimal risk of bias. Each obstacle is discussed in turn,
highlighting some suggested solutions and current initiatives
working towards improvements in these areas. Some exam-
ples of good practice in this field are also discussed.
Conclusions Many of the historical problems with surgical
trial outcomes may be overcome with an increased under-
standing of the trial design and purpose and recognition that
pragmatic trials require assessments of outcomes that are
patient-centred in addition to measurement of short-term out-
comes. The use of core outcome sets developed for specific
surgical interventions and the application of novel methods to
blind outcome assessors will also improve outcome measure-
ment and reporting. It is recommended that surgeons work
together with trial methodologists to integrate these ap-
proaches into RCTs in surgery. This will facilitate the
appropriate evaluation of surgical interventions with informa-
tive outcomes so that results from trials can be useful for
clinical practice.
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Introduction
Randomised controlled trials (RCTs) in surgery are uncom-
mon and often more complex and difficult to design and
implement than trials of pharmaceutical interventions. The
reasons for this include challenges with recruitment (due to
lack of clinical equipoise or treatment preference), difficulties
with standardisation and delivery of interventions between
trial centres or individual surgeons (particularly if the inter-
ventions under evaluation are new) [1, 2], and challenges
concerning the appropriate selection, measurement and
reporting of outcomes.
An outcome (or endpoint) is a direct or indirect measure-
ment of the effect of an intervention on a participant’s clinical
or functional status [3, 4]. The purpose of outcome measure-
ments in an RCT is to provide information about the effect of
an intervention under evaluation compared to a standard pro-
cedure or control. In a trial, participants are randomised to
receive different interventions with the aim of negating the
effect of confounding factors. In this way, any observed
differences in outcome between the treatment groups can be
attributed to the effect of the intervention and not to a baseline
characteristic of the participant or other potentially influential
variable. When designing a clinical trial, it is necessary to
define a trial hypothesis of the expected effect of the interven-
tion on a primary outcome (the outcome of greatest interest).
This allows the calculation of a sample size which is essential
to inform the number of centres in the trial and the length of
trial recruitment. In some trials, it may be advantageous to
have a composite primary outcome comprised of more than
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one outcome of interest. This can be advantageous when event
rates are low, to allow for smaller sample size calculation and
increased statistical efficacy, or when the choice between sev-
eral important outcomes is arbitrary [5]. Limitations of using a
composite outcome, however, include the need for a more
complex statistical analysis plan and ensuring that all compo-
nent outcomes have equal importance to patients [6, 7].
Secondary outcomes are measured to evaluate the additional
effects of the intervention and answer other relevant questions
[8]. They may also be chosen for exploratory purposes in order
to develop a hypothesis for future research. Outcomes may be
classified with regard to their type (primary, secondary, or
exploratory), and whether they are assessed objectively or
influenced by patient or clinician judgement [9]. Theymay also
be categorised by the domain of measurement. Clinical out-
comes may be defined as outcomes measured in clinical prac-
tice such as survival/mortality or surgical complications and
adverse events (e.g. anastomotic leak or deep vein thrombosis).
Clinical outcomes can be completely objective (e.g. death) or
they can include a professional assessment or observer inter-
pretation (e.g. wound infection). Other types of outcomes may
be patient-reported outcomes (PROs); assessments made di-
rectly by the patient themselves rather than an observer, such as
symptom severity or reports of functional health status. Most
PROs are recorded in self-completed questionnaires with vali-
dated rating scales that are standardised and scored and are
often referred to as measures of health-related quality of life
(HRQL). Whilst some outcomes may be referred to as HRQL
outcomes, this term is confusing, and it is recommended that
outcomes are described as PROs (measured by patients them-
selves), or observer assessed outcomes (measured by clinicians/
researchers), rather than the ill-defined term HRQL—which
may be measured by a patient or an observer. Surrogate out-
comes are outcomes that predict another clinically meaningful
endpoint of interest [10] and may be used because they are
more practical or less invasive, for example, the measurement
of coagulation factors or albumin as a surrogate marker of liver
function in patients following liver surgery [11]. Other types of
outcomes include hospital or ‘process’-related factors such as
length of hospital stay or frequency of tests, and assessments of
cost and resource use (Box 1).
Many of these different types of outcomes can be assessed
once or on several occasions following surgery. The timing of
outcome assessment varies in trials, and can be classified as
during or after surgery, as short, medium or long-term. Short-
term assessments are often made during the hospital stay and
longer-term assessments maybe years after the intervention. In
the selection of outcomes for RCTs in surgery, it is necessary
to consider these different types of outcomes, who will assess
them, and the appropriate time to assess them in light of the
research question and trial design.
Historically, surgeons have selected and assessed out-
comes that focus on short-term clinical events and those
related to the surgical process such as complication rates
and length of hospital stay [12]. This may be because these
outcomes reflect aspects of patient outcome and recovery
that are of importance to the surgeons designing the study,
and reflect the quality of the delivery of the intervention
and the surgeons’ technical skill [13]. They are also events
that require early detection and treatment by surgeons,
which may result in serious problems for patients if un-
treated. Whilst it is important to assess and report these
short-term clinical outcomes, many surgical studies do not
examine the longer-term benefits and harms of surgical
interventions or consider outcomes from a patient perspec-
tive [14]. In addition, undue focus on operative complica-
tions may be unhelpful as these outcomes are often rare,
and if trials are not powered sufficiently to exclude differ-
ences in uncommon complications, the data can be mis-
leading. There is, therefore, a need for better standards of
outcome selection, measurement and reporting in RCTs in
surgery. This paper will consider some of the key chal-
lenges and suggest solutions to these problems, highlighting
current initiatives working towards improvements in these
areas.
Challenges for outcome measurement in RCTs in surgery
The methodological and practical challenges for the selection
and measurement of outcomes in surgical trials include choos-
ing the right outcome for the trial design and purpose,
selecting relevant outcomes to measure from the range of
possible outcomes and measuring them with minimal risk of
bias.
Choosing relevant outcomes to suit the trial design
and purpose
In order to select the most appropriate outcomes for any trial, it
is first necessary to have a good understanding of the research
hypothesis. This will determine the trial design and the appro-
priate outcomes to be measured. Trials can be broadly classi-
fied as explanatory or pragmatic in design. Explanatory
(efficacy) trials are designed to test whether an intervention
works under ideal conditions (performed by an experienced
surgeon, for example, in a single centre with standardised pre-
and post-operative care) and for these reasons, the intervention
is delivered within a very restrictive protocol often on a highly
select group of patients [2, 15]. Outcomes in explanatory trials
are selected to provide information on whether the interven-
tion works within these restricted conditions and tend to focus
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on measurable clinical or biological symptoms or markers
[16]. For surgical trials, these are typically short-term clinical
or process measures that supply data about the safety of the
intervention and its immediate health benefits and risks.
Examples include measured changes in intra-operative vari-
ables (e.g. length of operation, blood loss) or short-term
adverse events and in-hospital morbidity (e.g. need for pain
killers, length of hospital stay) (Table 1, [17]). Pragmatic
clinical (effectiveness) trials, on the other hand, are designed
to assess whether an intervention works in routine clinical
practice and everyday settings. The intervention is delivered
under more flexible conditions and by practitioners with a
range of expertise to reflect typical practice. Members of the
research team, such as the surgeons, often have more scope to
make choices about the exact procedure performed, or the
approach used (depending on the research intervention). The
sample population is usually less restricted and in combina-
tion, these factors aim to make the results generalisable to a
wide range of clinical environments. Pragmatic trials often
provide information on the longer-term health gains and
harms of an intervention and results are used to inform pa-
tients, clinicians and policy makers whenmaking decisions on
treatment. A wide spectrum of outcomes can be assessed
during a pragmatic trial and an assessment of resource use
may also be included. The majority of RCTs in surgery aim to
determine if the intervention should be performed in standard
clinical practice and therefore, a pragmatic trial design is often
most appropriate [18]. However, reviews of the surgical liter-
ature show that the number of high-quality pragmatic trials is
few and often focus on short-term and clinical measures
providing uncertain value for patients, surgeons and other
decision makers [19–23]. Although there is a paucity of
studies, there are examples of well designed and conducted
pragmatic RCTs in surgery with appropriate outcome mea-
sures (Table 1). There are also examples of trials using com-
posite outcomes combining short-term measures and includ-
ing some longer-term assessments [24]. However, more high-
quality RCTs in surgery are required with better trial design
and outcome measures to allow the results to be relevant to
routine clinical practice. This will require that surgeons in-
volved in trial design to consider which outcomes are impor-
tant to patients and include assessment of these in trials as well
as the standard measures used to evaluate surgery.
Multicentre, pragmatic trials require surgeons to work to-
gether and to involve patients and other health-care profes-
sionals in the trial design process at an early stage. The
National Institute for Health Research (NIHR) in the UK funds
an advisory group to support greater public and patient involve-
ment in research [25] and the James Lind Alliance charitable
organisation aims to bridge the gap between patients and re-
searchers [26]. A similar initiative in Canada, the Patient-
Centred Outcomes Research Institute, encourages the involve-
ment of patients to shape the research agenda [27]. In the UK,
recent funding opportunities from the NIHR and Royal College
of Surgeons of England for Surgical Trial Centres [28] are also
promoting collaborative working, and there are trainee research
collaboratives whose purpose is to bring together surgical
trainees and offer the opportunity to run multicentre trials [29,
30]. Drives to bring together surgeons and methodologists and
to educate the surgical community in clinical trial design have
been generated. Examples of this include the international
IDEAL collaboration [31], the UK Medical Research Council
Hubs for Trials Methodology Research [32] and the American
College of Surgeons Continuous Quality Improvement
Surgical Research Committee [33]. In Germany, the Study
Centre for the German Surgical Society has similar aims to
increase the number of well-designed multicentre surgical trials
[34]. These initiatives should lead to improvements in the
design of randomised trials of surgical interventions.
Selecting and reporting appropriate outcome measures
for RCTs in surgery
After establishing the trial design and relevant outcomes, the
next challenge for RCTs in surgery is to clearly define and
select the outcomes to be measured from the range of possibil-
ities. In surgical studies, the approach to outcome assessment
has historically been assorted, inconsistent and ill-defined. A
systematic review of adverse events after gastrointestinal sur-
gery, for example, identified 56 different definitions and mea-
sures for anastomotic leak [35] and up to 10 different measures
for mortality have been used in studies after oesophagectomy
[23]. In colorectal cancer surgery, a systematic review found
766 different clinical outcomes were assessed, with inconsis-
tency in selection, measurement and reporting [36]. This vari-
ation across trials and lack of standardisation is problematic for
systematic reviews and meta-analyses of surgical interventions
as outcomes are often not comparable, meaning synthesis and
amalgamation of findings is seldom possible. In addition to
inconsistent outcome measurements, other problems for RCTs
in surgery are caused by the multiplicity of outcomes that are
measured in a single trial. As a result, authors of trial reports do
not always include the full range of outcomes that have been
measured, often focusing on outcomes with ‘interesting’ or
statistically significant results [37, 38]. Such selective reporting
of outcomes leads to outcome reporting bias and causes further
problems for systematic reviews by distorting the available
evidence [39–41]. Outcome reporting bias is a particular issue
for PROs, where numerous multiple health domains are mea-
sured within a single questionnaire and those of particular
interest are often not specified a priori or when PROs are
secondary outcomes.
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Core outcome sets (COSs) are one solution to the
problems caused by multiple outcome selection and out-
come reporting bias. Core outcome sets are a collection of
the important (core) outcomes to be measured and report-
ed in all pragmatic trials of a specific disease or condition,
and their use and application allows for the results from
multiple trials to be readily combined and compared. Core
outcomes are agreed by consensus between key stake-
holders such as patients, health-care professionals, and
members of funding bodies. The Core Outcome
Measures for Effectiveness Trials (COMET) Initiative in
the UK supports the development and application of COSs
and holds a database of all existing work in this area [42].
Several COSs to use in trials of surgical intervention are
being developed, for example in oesophageal, colorectal
and head and neck cancer as well as other diseases outside
oncology [42–44].
Assessing and measuring outcomes with minimal risk of bias
Once the outcomes to be measured are agreed upon and
defined, it is necessary to ensure that they are assessed appro-
priately to reduce the risk of bias. Bias can exaggerate treat-
ment effect, thereby making trial results unreliable and prob-
lematic when implementing for clinical practice [9].
Consideration must be given to how outcomes are measured
and by whom. It is also important that the tools used to assess
these outcomes are developed, tested, and validated properly,
as the use of inappropriate tools result in unreliable or invalid
data. This applies to any outcome measure being used in a
trial, whether it be a clinical measure of anastomotic leak, for
example, or a PRO.
There are several forms of bias from which surgical trials
are particularly at risk, including performance bias and as-
certainment bias. Performance bias results from differences
in the way patients in the two treatment arms are managed
post-operatively. It can have an effect on all types of out-
comes, and is a particular problem in trials of surgical
interventions because of the intimate role played in both
delivery of the intervention and post-operative care provision
by the operating surgeon. Ascertainment bias is a term used
to describe collectively observer bias (when outcomes are
reported by an outcome assessor) and reporting bias (for
PROs), and can be a particular problem in trials whose
primary outcome is a PRO. Both performance and observer
bias can occur on a conscious or sub-conscious level and
might result from pre-existing expectations about the effica-
cy of the treatments under evaluation, a lack of clinical
equipoise or the influence of knowledge about treatment
allocation. One method that can be used to minimise the risk
of both performance and ascertainment bias is blinding (or
masking). Blinding is used in RCTs to hide treatment allo-
cation from various members of the research team or trial
participants. In the ideal setting, blinding is maintained until
all primary outcome data are collected. The decision about
who should be blinded in a particular trial depends on the
trial design, interventions and available funding. In pharma-
cological trials, it is common to use a matched placebo to
blind staff and patients. In the case of surgical trials, howev-
er, using a placebo or sham surgery is often difficult or
impossible because it may be considered unethical to subject
patients to general anaesthesia and a mock operation for
solely research purposes, although such examples exist
[45–51]. The complex nature of surgery can also make
blinding of staff difficult because of the necessity for input
from a large multidisciplinary team and it is frequently
impossible for surgeons to be blinded because of their role
in delivery of the intervention. In this case, where ever
possible, it is recommended that the surgeon does not collect
the outcome data and that it is collected by someone blinded
to the intervention type.
Despite these challenges for surgical RCTs, novel
methods may be effectively employed to blind some of
the research team. Examples where this has been success-
fully achieved are illustrated in Table 2 [49, 52–57]. In a
trial whose primary outcome measure is a PRO, it is
important to consider whether it is possible to blind the
patient from the treatment allocation, although this may
also be impossible. It may be more practical in this
situation to blind outcome assessors who are ideally inde-
pendent from the central research team. For example, an
adjudicating committee may be used to review and assess
digitalized clinical, photographic or imaging data with no
details of the patient or intervention available to them
[57].
Summary and conclusion
Well designed and conducted pragmatic RCTs are essential for
the evaluation of surgical interventions. Central to this is the
need to select, define, measure and report outcomes that are
relevant to the trial design, valid and reliable, and to assess
these outcomes with minimal ascertainment and performance
bias. This can be achieved with surgeons and methodologists
working closely together. The need to improve and increase
the number of surgical trials has been internationally
recognised and a cultural shift in the approach to trial design
and participation is taking place. The development and appli-
cation of core outcome sets for pragmatic RCTs in surgerywill
reduce many of the problems associated with the inconsisten-
cy and multiplicity of outcomes that have historically been
assessed in RCTs in surgery and this is being addressed by
work of the COMET initiative. Finally, the challenge to reduce
and eliminate bias in surgical trials is being tackled by inno-
vative methods to perform blinding to ensure that outcomes
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are fairly assessed and measured and effects of the interven-
tion are not over or under estimated. These combined ap-
proaches and efforts will ensure surgical interventions are
appropriately evaluated with informative outcomes, so that
results can be useful for clinical practice.
Box 1. Types of outcomes and outcome measures used in
RCTs in surgery
Clinical outcome measure
An outcome measured in clinical practice, e.g. survival or surgical
complications such as anastomotic leak, including the specific
measurement variable (e.g. systolic blood pressure), analysis metric
(e.g. change from baseline, final value, time to event), method of
aggregation (e.g. median, proportion) and timepoint [58].
Patient reported outcome (PRO)
An outcome reported directly by the patient themselves without
interpretation from an observer [59]. Examples include
assessments of health status and quality of life (e.g. physical
ability, symptom severity). PROs are typically recorded in a
self-completed questionnaire.
Patient-reported outcome measure
A measure of a PRO including domain (e.g. anxiety), specific
measurement tool (e.g. name of questionnaire) and other levels of
specification required for clinical outcomes (analysis metric and
method of aggregation) [60].
Hospital/process-related outcome
Ametric related to the organisation or individual involved in the patients’
care rather than the effect of the intervention on the patient’s health, e.g.
length of hospital stay or number of tests conducted.
Resource use measure
A metric to quantify the cost of care, including direct financial expenses
as well as staff time.
Surrogate outcome
A measure that is not of direct practical importance but is believed to
reflect an outcome that is important; often a physiological or
biochemical marker that can be relatively quickly and easily measured,
and that is taken as being predictive of an important clinical outcome
[3].
Composite outcome
An outcome that consists of two or more component outcomes [5].
Primary outcome
The outcome of greatest importance [3].
Secondary outcome
An outcome used to evaluate additional effects of the intervention deemed
a priori as being less important than the primary outcomes [3].
Explanatory outcome
Outcomes that are measured to provide additional information about an
intervention, but may be without an a priori hypothesis.
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